| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
75,303 |
66,177 |
$11.15M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
54,356 |
49,614 |
$7.97M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
41,108 |
36,149 |
$6.81M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
15,210 |
12,389 |
$4.88M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
67,183 |
22,426 |
$4.01M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
11,333 |
10,610 |
$1.85M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
10,446 |
9,673 |
$1.54M |
| G0378 |
Hospital observation service, per hour |
22,228 |
12,126 |
$1.53M |
| 70450 |
Computed tomography, head or brain; without contrast material |
13,054 |
12,048 |
$1.45M |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
40,667 |
14,643 |
$1.43M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
11,091 |
6,266 |
$1.27M |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
1,570 |
1,488 |
$1.22M |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
5,766 |
3,072 |
$1.01M |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
2,471 |
2,329 |
$900K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
5,322 |
5,018 |
$806K |
| 93971 |
|
3,658 |
3,464 |
$771K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
1,332 |
1,267 |
$720K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
5,352 |
3,136 |
$625K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
6,519 |
6,072 |
$623K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
8,826 |
8,702 |
$622K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,151 |
3,716 |
$565K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
5,297 |
4,944 |
$564K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
18,814 |
15,214 |
$559K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
5,103 |
4,352 |
$539K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
3,669 |
3,331 |
$515K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
3,228 |
3,045 |
$489K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
4,538 |
4,294 |
$478K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
9,696 |
4,747 |
$471K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
6,892 |
6,614 |
$405K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
90,905 |
71,094 |
$395K |
| 71046 |
Radiologic examination, chest; 2 views |
38,393 |
35,100 |
$394K |
| 97162 |
|
8,785 |
8,163 |
$373K |
| 59025 |
Fetal non-stress test |
1,635 |
1,273 |
$349K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
781 |
752 |
$349K |
| 76830 |
Ultrasound, transvaginal |
2,984 |
2,847 |
$334K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
3,893 |
3,635 |
$331K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
12,190 |
10,755 |
$308K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,647 |
1,108 |
$284K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
9,670 |
9,543 |
$276K |
| 10060 |
|
1,635 |
1,530 |
$275K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
8,336 |
7,287 |
$270K |
| 76770 |
|
2,037 |
1,934 |
$257K |
| 93017 |
|
3,808 |
3,586 |
$254K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
4,692 |
2,059 |
$218K |
| 93970 |
|
851 |
794 |
$205K |
| 84484 |
|
37,328 |
24,637 |
$179K |
| 76536 |
|
1,508 |
1,449 |
$169K |
| 76642 |
|
1,498 |
1,332 |
$163K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,463 |
1,377 |
$155K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
36,583 |
29,269 |
$149K |
| 97161 |
|
2,625 |
2,488 |
$149K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
700 |
382 |
$132K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
1,273 |
561 |
$130K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
327 |
313 |
$130K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
72,704 |
53,432 |
$127K |
| 73630 |
|
6,700 |
5,784 |
$125K |
| 77080 |
|
2,445 |
2,402 |
$125K |
| 97535 |
Self-care/home management training, each 15 minutes |
5,006 |
2,708 |
$124K |
| ATP08 |
|
16,171 |
12,840 |
$123K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
695 |
651 |
$120K |
| 97166 |
|
2,635 |
2,392 |
$118K |
| 97116 |
|
4,996 |
3,053 |
$111K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
4,345 |
4,132 |
$106K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
4,321 |
4,106 |
$105K |
| 83690 |
|
23,528 |
20,966 |
$103K |
| ATP14 |
|
9,196 |
8,189 |
$91K |
| 81025 |
|
16,364 |
15,144 |
$89K |
| 95811 |
|
111 |
110 |
$87K |
| 12001 |
|
443 |
425 |
$86K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
135 |
133 |
$83K |
| 73030 |
|
4,392 |
3,993 |
$78K |
| 72100 |
|
2,764 |
2,653 |
$76K |
| 83880 |
|
5,326 |
4,770 |
$74K |
| 82553 |
|
13,932 |
11,070 |
$74K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
4,184 |
3,884 |
$74K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
44,554 |
36,921 |
$70K |
| 0002A |
|
2,628 |
2,416 |
$69K |
| 80053 |
Comprehensive metabolic panel |
25,698 |
22,442 |
$67K |
| J1756 |
Injection, iron sucrose, 1 mg |
2,255 |
670 |
$65K |
| 96367 |
|
1,093 |
753 |
$65K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
602 |
578 |
$64K |
| 83605 |
|
12,536 |
9,241 |
$64K |
| 87088 |
|
12,880 |
11,681 |
$64K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
162 |
156 |
$64K |
| 73130 |
|
4,393 |
3,888 |
$63K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
26,205 |
18,791 |
$60K |
| 0001A |
|
2,914 |
2,689 |
$60K |
| 73560 |
|
2,847 |
2,400 |
$56K |
| 90715 |
|
2,388 |
2,286 |
$55K |
| 73610 |
|
4,216 |
3,798 |
$54K |
| G0399 |
Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation |
562 |
528 |
$52K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
6,677 |
5,165 |
$52K |
| ATP09 |
|
6,081 |
5,216 |
$49K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
5,381 |
5,013 |
$49K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
331 |
315 |
$49K |
| 29125 |
|
417 |
385 |
$48K |
| ATP15 |
|
4,967 |
4,364 |
$48K |
| 73562 |
|
2,948 |
2,584 |
$48K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
103 |
103 |
$47K |
| 86850 |
|
8,287 |
7,640 |
$46K |
| 97035 |
|
783 |
351 |
$44K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
281 |
268 |
$44K |
| 84443 |
Thyroid stimulating hormone (TSH) |
5,484 |
4,940 |
$43K |
| 83735 |
|
13,493 |
9,358 |
$41K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
91 |
86 |
$40K |
| 73110 |
|
2,516 |
2,223 |
$40K |
| 81001 |
|
19,539 |
17,759 |
$38K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,510 |
2,338 |
$37K |
| 93880 |
|
420 |
409 |
$37K |
| 96415 |
|
199 |
143 |
$36K |
| G0121 |
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk |
71 |
68 |
$35K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
27,672 |
20,617 |
$35K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,027 |
2,911 |
$33K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
450 |
412 |
$33K |
| 73502 |
|
2,211 |
2,047 |
$33K |
| 94729 |
|
1,227 |
1,204 |
$33K |
| 12002 |
|
153 |
147 |
$33K |
| 86900 |
|
8,349 |
7,691 |
$32K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
7,270 |
6,818 |
$32K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
1,534 |
953 |
$31K |
| 84702 |
|
2,567 |
2,295 |
$30K |
| 97163 |
|
656 |
602 |
$30K |
| 70486 |
|
631 |
607 |
$30K |
| 85027 |
|
11,171 |
7,838 |
$30K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
16,189 |
14,094 |
$30K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
11,949 |
9,936 |
$28K |
| 64483 |
|
61 |
54 |
$28K |
| 71250 |
|
456 |
414 |
$27K |
| 85379 |
|
4,482 |
4,188 |
$27K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
205 |
194 |
$26K |
| 70496 |
|
155 |
145 |
$26K |
| J1644 |
Injection, heparin sodium, per 1000 units |
18,340 |
5,550 |
$25K |
| 94060 |
|
223 |
211 |
$25K |
| H0035 |
Mental health partial hospitalization, treatment, less than 24 hours |
104 |
12 |
$24K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
5,688 |
2,281 |
$23K |
| 71045 |
Radiologic examination, chest; single view |
4,598 |
4,050 |
$23K |
| 85730 |
|
8,716 |
7,778 |
$23K |
| 87070 |
|
4,387 |
3,864 |
$22K |
| 85610 |
|
13,143 |
10,606 |
$22K |
| J7050 |
Infusion, normal saline solution, 250 cc |
6,690 |
3,541 |
$22K |
| 12011 |
|
110 |
105 |
$21K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
7,522 |
5,766 |
$20K |
| 87081 |
|
4,333 |
3,536 |
$20K |
| 87186 |
|
4,090 |
3,588 |
$20K |
| 99219 |
|
26 |
26 |
$19K |
| 88307 |
|
315 |
307 |
$19K |
| 87040 |
|
3,409 |
1,544 |
$18K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
11,545 |
8,683 |
$18K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
4,313 |
3,855 |
$17K |
| 74018 |
|
555 |
516 |
$16K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
19,732 |
18,048 |
$16K |
| 82803 |
|
1,676 |
1,377 |
$16K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
6,421 |
3,841 |
$16K |
| 97113 |
|
336 |
123 |
$16K |
| 82550 |
|
27,913 |
21,377 |
$16K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
14,770 |
8,090 |
$15K |
| 11043 |
|
74 |
42 |
$15K |
| 86901 |
|
8,321 |
7,667 |
$14K |
| 73140 |
|
660 |
608 |
$14K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
1,407 |
1,163 |
$14K |
| ATP16 |
|
1,470 |
1,294 |
$14K |
| S9485 |
Crisis intervention mental health services, per diem |
73 |
64 |
$13K |
| 81003 |
|
10,223 |
9,551 |
$13K |
| 81002 |
|
6,951 |
6,575 |
$13K |
| 90791 |
Psychiatric diagnostic evaluation |
1,470 |
1,269 |
$13K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
14,068 |
11,214 |
$13K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
2,850 |
2,389 |
$11K |
| 87210 |
|
2,861 |
2,674 |
$11K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
3,843 |
3,499 |
$11K |
| 73080 |
|
872 |
802 |
$11K |
| 95816 |
|
45 |
43 |
$11K |
| 93923 |
|
139 |
130 |
$10K |
| 20610 |
|
69 |
63 |
$10K |
| 43235 |
|
26 |
26 |
$10K |
| J2704 |
Injection, propofol, 10 mg |
2,590 |
2,314 |
$10K |
| 80076 |
|
13,147 |
11,441 |
$9K |
| 82330 |
|
1,911 |
1,579 |
$9K |
| 76870 |
|
85 |
82 |
$9K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,833 |
1,706 |
$9K |
| 88342 |
|
2,096 |
1,980 |
$9K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
5,377 |
3,711 |
$9K |
| 71271 |
|
200 |
194 |
$8K |
| 84703 |
|
1,573 |
1,449 |
$8K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
3,323 |
3,079 |
$8K |
| 94010 |
|
129 |
125 |
$8K |
| 94726 |
|
160 |
152 |
$8K |
| 93454 |
|
15 |
15 |
$8K |
| 90999 |
Unlisted dialysis procedure, inpatient or outpatient |
127 |
12 |
$7K |
| 0031A |
|
289 |
262 |
$7K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
71 |
65 |
$7K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
139 |
138 |
$6K |
| 90686 |
|
462 |
418 |
$6K |
| 87077 |
|
1,700 |
1,540 |
$6K |
| 82565 |
|
6,468 |
5,664 |
$5K |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
2,371 |
2,227 |
$5K |
| 82962 |
|
39,821 |
15,131 |
$5K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
1,904 |
858 |
$5K |
| 84100 |
|
10,133 |
6,935 |
$5K |
| 82947 |
|
5,935 |
5,259 |
$5K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
28 |
26 |
$5K |
| 77065 |
Tomosynthesis, mammo |
119 |
106 |
$4K |
| 86140 |
|
1,907 |
1,580 |
$4K |
| 90674 |
|
308 |
285 |
$4K |
| J2560 |
Injection, phenobarbital sodium, up to 120 mg |
162 |
84 |
$4K |
| 84520 |
|
5,396 |
4,267 |
$4K |
| 94727 |
|
66 |
65 |
$4K |
| 36430 |
|
13 |
12 |
$3K |
| J2785 |
Injection, regadenoson, 0.1 mg |
1,724 |
1,599 |
$3K |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
527 |
470 |
$3K |
| 71101 |
|
490 |
475 |
$3K |
| 85651 |
|
1,966 |
1,652 |
$3K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,766 |
1,338 |
$3K |
| 73590 |
|
417 |
380 |
$3K |
| 20552 |
|
14 |
14 |
$3K |
| 88304 |
|
536 |
522 |
$3K |
| 82310 |
|
4,199 |
3,804 |
$3K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
26 |
26 |
$3K |
| 70498 |
|
170 |
160 |
$3K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
1,709 |
1,587 |
$3K |
| 96376 |
|
5,446 |
4,442 |
$3K |
| 83970 |
|
640 |
513 |
$3K |
| 84295 |
|
5,566 |
4,907 |
$3K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
2,764 |
1,294 |
$3K |
| 84450 |
|
2,142 |
1,853 |
$2K |
| 84460 |
|
2,224 |
1,931 |
$2K |
| 74220 |
|
25 |
25 |
$2K |
| 76942 |
|
14 |
14 |
$2K |
| 82435 |
|
3,863 |
3,546 |
$2K |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
1,014 |
940 |
$2K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
1,562 |
1,403 |
$2K |
| 93798 |
|
54 |
14 |
$2K |
| 82374 |
|
3,150 |
2,960 |
$2K |
| 64484 |
|
13 |
13 |
$2K |
| 80061 |
Lipid panel |
2,780 |
2,498 |
$2K |
| 77336 |
|
29 |
12 |
$2K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
1,088 |
800 |
$2K |
| 84439 |
|
415 |
368 |
$2K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
1,842 |
995 |
$2K |
| 77002 |
|
24 |
24 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
14,148 |
9,587 |
$2K |
| 72040 |
|
28 |
26 |
$2K |
| 77062 |
|
12 |
12 |
$2K |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
826 |
736 |
$2K |
| 29515 |
|
12 |
12 |
$2K |
| 82247 |
|
1,544 |
1,326 |
$2K |
| 84132 |
|
2,912 |
2,235 |
$1K |
| J2060 |
Injection, lorazepam, 2 mg |
1,625 |
1,106 |
$1K |
| 70491 |
|
13 |
12 |
$1K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
2,411 |
1,285 |
$1K |
| ATP10 |
|
145 |
127 |
$1K |
| 74019 |
|
122 |
114 |
$984.67 |
| 82040 |
|
1,272 |
1,118 |
$947.07 |
| 85014 |
|
1,478 |
1,241 |
$932.35 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
378 |
283 |
$919.97 |
| 82728 |
|
681 |
563 |
$907.76 |
| 73090 |
|
259 |
232 |
$844.35 |
| 87340 |
|
685 |
553 |
$844.00 |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
337 |
325 |
$836.03 |
| 97164 |
|
29 |
25 |
$829.70 |
| 96411 |
|
41 |
24 |
$801.15 |
| 87205 |
|
325 |
274 |
$784.00 |
| 72070 |
|
28 |
25 |
$767.29 |
| 90714 |
|
45 |
43 |
$766.77 |
| A9270 |
Non-covered item or service |
22,582 |
14,302 |
$765.87 |
| S0028 |
Injection, famotidine, 20 mg |
731 |
634 |
$765.38 |
| 84075 |
|
1,221 |
1,077 |
$751.08 |
| 77066 |
Tomosynthesis, mammo |
93 |
93 |
$744.60 |
| 82570 |
|
221 |
190 |
$738.48 |
| Q5105 |
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units |
1,298 |
100 |
$738.21 |
| 83550 |
|
792 |
671 |
$735.29 |
| 84112 |
|
12 |
12 |
$700.93 |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
934 |
618 |
$695.46 |
| 84155 |
|
1,209 |
1,067 |
$628.05 |
| A9576 |
Injection, gadoteridol, (prohance multipack), per ml |
115 |
102 |
$553.38 |
| V2632 |
Posterior chamber intraocular lens |
455 |
435 |
$547.24 |
| G0410 |
Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes |
399 |
50 |
$529.34 |
| ATP03 |
|
324 |
291 |
$529.05 |
| 96417 |
|
78 |
49 |
$519.81 |
| C1769 |
Guide wire |
1,732 |
1,615 |
$519.63 |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
1,236 |
1,130 |
$426.19 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
1,299 |
1,138 |
$353.83 |
| 72131 |
|
13 |
13 |
$348.57 |
| J3372 |
Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg |
166 |
73 |
$340.98 |
| 73660 |
|
12 |
12 |
$315.32 |
| ATP07 |
|
42 |
38 |
$305.16 |
| 87147 |
|
110 |
81 |
$302.45 |
| J3470 |
Injection, hyaluronidase, up to 150 units |
191 |
182 |
$297.54 |
| 81015 |
|
202 |
175 |
$233.55 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
34 |
13 |
$227.32 |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
568 |
506 |
$203.17 |
| 86618 |
|
17 |
14 |
$201.89 |
| 80164 |
|
34 |
25 |
$195.72 |
| J0694 |
Injection, cefoxitin sodium, 1 gm |
140 |
79 |
$186.78 |
| 87075 |
|
44 |
37 |
$178.40 |
| J1630 |
Injection, haloperidol, up to 5 mg |
783 |
623 |
$176.88 |
| 73552 |
|
13 |
13 |
$171.90 |
| 0011A |
|
28 |
28 |
$169.40 |
| 84550 |
|
154 |
127 |
$167.23 |
| J3371 |
Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg |
181 |
102 |
$155.11 |
| 84156 |
|
47 |
37 |
$136.08 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
58 |
52 |
$127.21 |
| J1790 |
Injection, droperidol, up to 5 mg |
232 |
187 |
$123.35 |
| 86803 |
|
61 |
51 |
$102.04 |
| 82607 |
|
14 |
14 |
$92.58 |
| 82746 |
|
12 |
12 |
$91.02 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
5,292 |
4,438 |
$74.91 |
| 73060 |
|
28 |
27 |
$73.55 |
| 82140 |
|
15 |
12 |
$48.13 |
| 82010 |
|
17 |
13 |
$43.26 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
2,412 |
1,594 |
$41.01 |
| C9113 |
Injection, pantoprazole sodium, per vial |
1,168 |
537 |
$39.31 |
| 86706 |
|
49 |
41 |
$32.30 |
| 86704 |
|
50 |
40 |
$23.42 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
1,328 |
1,144 |
$18.46 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
547 |
503 |
$13.91 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
162 |
111 |
$7.50 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
476 |
437 |
$1.99 |
| 99152 |
|
12 |
12 |
$1.78 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
125 |
111 |
$1.61 |
| J3411 |
Injection, thiamine hcl, 100 mg |
31 |
24 |
$0.00 |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
523 |
456 |
$0.00 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
560 |
465 |
$0.00 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
401 |
361 |
$0.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
28 |
26 |
$0.00 |
| J3480 |
Injection, potassium chloride, per 2 meq |
22 |
12 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
117 |
115 |
$0.00 |
| J1270 |
Injection, doxercalciferol, 1 mcg |
125 |
12 |
$0.00 |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
14 |
12 |
$0.00 |
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
128 |
13 |
$0.00 |
| 0012A |
|
24 |
24 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
1,434 |
1,214 |
$0.00 |
| 91300 |
|
177 |
159 |
$0.00 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
213 |
197 |
$0.00 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
116 |
113 |
$0.00 |
| G8989 |
Self care functional limitation, discharge status, at discharge from therapy or to end reporting |
31 |
26 |
$0.00 |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
201 |
179 |
$0.00 |
| C1776 |
Joint device (implantable) |
71 |
64 |
$0.00 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
58 |
44 |
$0.00 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
26 |
24 |
$0.00 |
| 94664 |
|
17 |
13 |
$0.00 |
| C8921 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; complete |
39 |
35 |
$0.00 |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
13 |
12 |
$0.00 |